Dicerna Pharmaceuticals Receivables

Dicerna Pharmaceuticals (DRNA) currently reports a receivables of $6.2M as of September 2021. That compares with $6M in the prior-year period — up 4.1% year over year. Use the charts on this page to explore Dicerna Pharmaceuticals's receivables history and peer comparisons.

Dicerna Pharmaceuticals's receivables increased from $6M to $6.2M — a 4.1% year-over-year increase (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Dicerna Pharmaceuticals reported $6.2M in receivables as of September 2021. That compares with $6M in the prior-year period — up 4.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $6.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Dicerna Pharmaceuticals, and consider following DRNA for alerts when major investors trade the stock.

Dicerna Pharmaceuticals is classified in the Healthcare sector. On receivables, it currently shows $6.2M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DRNA with unrelated industries.